Skip to content
Screener

AbbVie ABBV Q3 2025 earnings

Reported October 31, 2025 · Before market open

Revenue$15.8BBeat by $190.2M
EPS$1.86Beat by $0.09
Revenue estimate$15.6B
EPS estimate$1.77

Next report

Oct 30, 2026 (In 3 weeks)
Revenue estimate$17.3B
EPS estimate$3.86

Financials

Q3 2025

Income statement

See full
Revenue$15.8B+9.1%
Gross profit$10.5B+2.2%
Operating income$1.9B-50.3%
Net income$186.0M-88.1%
EPS (diluted)$0.10-88.6%

Balance sheet

See full
Cash & equivalents$5.6B-22.4%
Total debt$66.8B-6.1%
Total equity-$2.6B-144%
Total assets$133.90B-6.6%

Cash flow

See full
Operating cash flow$7.0B+29.0%
CapEx$381.0M+53.0%
Free cash flow$6.6B+27.8%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$409.03B+17.3%
Enterprise value$470.16B+13.9%
P/E171.3×+103×
P/S6.9×+0.6×

Profitability

See full
Gross margin69.7%+2.5pp
Net margin4%-5.2pp
FCF margin33%+4.9pp

Returns & leverage

See full
Current ratio0.7×+0.1×

Segments

By product

See full
Skyrizi$4.7B+46.9%
Rinvoq$2.2B+35.3%
Humira$993.0M-55.4%
Botox Therapeutic$985.0M+16.2%
Vraylar$934.0M+6.7%

FAQ

When did AbbVie report Q3 2025 earnings?
AbbVie (ABBV) reported Q3 2025 earnings on October 31, 2025 before market open.
What were AbbVie's Q3 2025 revenue and EPS?
AbbVie reported revenue of $15.8B and eps of $1.86 for Q3 2025.
Did AbbVie beat estimates in Q3 2025?
Revenue beat the consensus estimate of $15.6B by $190.2M. EPS beat the consensus estimate of $1.77 by $0.09.
How did AbbVie's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 9.1% from $14.5B a year earlier and eps declined 38.0% from $3.00.
Where can I find AbbVie's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001551152-25-000047) and the 10-Q periodic report (0001551152-25-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.